Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
Tóm tắt
Từ khóa
Tài liệu tham khảo
Sung, 2021, Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin, 71, 209, 10.3322/caac.21660
Kudo, 2018, Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial, Lancet, 391, 1163, 10.1016/S0140-6736(18)30207-1
Reig, 2014, Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib, J Hepatol, 61, 318, 10.1016/j.jhep.2014.03.030
Llovet, 2008, Sorafenib in advanced hepatocellular carcinoma, N Engl J Med, 359, 378, 10.1056/NEJMoa0708857
Hernandez-Gea, 2013, Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma, Gastroenterology, 144, 512, 10.1053/j.gastro.2013.01.002
Hou, 2020, The immunobiology of hepatocellular carcinoma in humans and mice: basic concepts and therapeutic implications, J Hepatol, 72, 167, 10.1016/j.jhep.2019.08.014
El-Khoueiry, 2018, Impact of antitumor activity on survival outcomes, and nonconventional benefit, with nivolumab in patients with advanced hepatocellular carcinoma: subanalyses of CheckMate-040, Proc Am Soc Clin Oncol, 36, 475, 10.1200/JCO.2018.36.4_suppl.475
Crocenzi, 2017, Nivolumab (nivo) in sorafenib (sor)-naive and -experienced pts with advanced hepatocellular carcinoma (HCC): CheckMate 040 study, Proc Am Soc Clin Oncol, 35
Finn, 2020, Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma, N Engl J Med, 382, 1894, 10.1056/NEJMoa1915745
Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026
1990, EuroQol--a new facility for the measurement of health-related quality of life, Health Policy, 16, 199, 10.1016/0168-8510(90)90421-9
Steel, 2006, Clinically meaningful changes in health-related quality of life in patients diagnosed with hepatobiliary carcinoma, Ann Oncol, 17, 304, 10.1093/annonc/mdj072
Pickard, 2007, Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer, Health Qual Life Outcomes, 5, 70, 10.1186/1477-7525-5-70
El-Khoueiry, 2017, Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial, Lancet, 389, 2492, 10.1016/S0140-6736(17)31046-2
Sangro, 2020, Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma, J Hepatol, 73, 1460, 10.1016/j.jhep.2020.07.026
Harding, 2019, Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies, Clin Cancer Res, 25, 2116, 10.1158/1078-0432.CCR-18-2293
Finn, 2020, Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial, J Clin Oncol, 38, 193, 10.1200/JCO.19.01307
Cainap, 2015, Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial, J Clin Oncol, 33, 172, 10.1200/JCO.2013.54.3298
Cheng, 2013, Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial, J Clin Oncol, 31, 4067, 10.1200/JCO.2012.45.8372
Johnson, 2013, Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study, J Clin Oncol, 31, 3517, 10.1200/JCO.2012.48.4410
Yau, 2020, Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial, JAMA Oncol, 6, 10.1001/jamaoncol.2020.4564
Zhu, 2018, Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial, Lancet Oncol, 19, 940, 10.1016/S1470-2045(18)30351-6
Finn, 2021, IMbrave150: updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC), Proc Am Soc Oncol, 39, 267
Kudo, 2021, Combination immunotherapy with anti-VEGF/TKI for hepatocellular carcinoma: present and future perspective, Hepatobiliary Surg Nutr, 10, 241, 10.21037/hbsn-20-707
Galle, 2018, EASL Clinical Practice Guidelines: management of hepatocellular carcinoma, J Hepatol, 69, 182, 10.1016/j.jhep.2018.03.019
Vogel, 2018, Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 29, iv238, 10.1093/annonc/mdy308
Kokudo, 2019, Clinical practice guidelines for hepatocellular carcinoma: the Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update, Hepatol Res, 49, 1109, 10.1111/hepr.13411
Kudo, 2021, Management of hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2021 Update, Liver Cancer, 10, 181, 10.1159/000514174
Omata, 2017, Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update, Hepatol Int, 11, 317, 10.1007/s12072-017-9799-9
Overman, 2017, Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study, Lancet Oncol, 18, 1182, 10.1016/S1470-2045(17)30422-9
Sharma, 2019, Nivolumab alone and with ipilimumab in previously treated metastatic urothelial carcinoma: CheckMate 032 nivolumab 1 mg/kg plus ipilimumab 3 mg/kg expansion cohort results, J Clin Oncol, 37, 1608, 10.1200/JCO.19.00538